Relay Therapeutics, Inc. (RLAY)

18.77 -3.35% (-0.65)

Over 1M: -0.3%

2026-08-28
19 20
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Q3 '21 — Revenue: 666K Q3 '21 — Operating Cash Flow: -53.2M Q3 '21 — Free Cash Flow: -54.9M Q3 '21 — Net Income: -60.8M Q4 '21 — Revenue: 567K Q4 '21 — Operating Cash Flow: -39.7M Q4 '21 — Free Cash Flow: -40.6M Q4 '21 — Net Income: -67.5M Q1 '22 — Revenue: 419K Q1 '22 — Operating Cash Flow: -49.2M Q1 '22 — Free Cash Flow: -52M Q1 '22 — Net Income: -62M Q2 '22 — Revenue: 365K Q2 '22 — Operating Cash Flow: -57.1M Q2 '22 — Free Cash Flow: -59M Q2 '22 — Net Income: -76.8M Q3 '22 — Revenue: 344K Q3 '22 — Operating Cash Flow: -66.1M Q3 '22 — Free Cash Flow: -68.2M Q3 '22 — Net Income: -84.2M Q4 '22 — Revenue: 253K Q4 '22 — Operating Cash Flow: -57.1M Q4 '22 — Free Cash Flow: -59.4M Q4 '22 — Net Income: -67.5M Q1 '23 — Revenue: 226K Q1 '23 — Operating Cash Flow: -67.1M Q1 '23 — Free Cash Flow: -69M Q1 '23 — Net Income: -94.2M Q2 '23 — Revenue: 119K Q2 '23 — Operating Cash Flow: -68.6M Q2 '23 — Free Cash Flow: -70.1M Q2 '23 — Net Income: -98.5M Q3 '23 — Revenue: 25.2M Q3 '23 — Operating Cash Flow: -75.4M Q3 '23 — Free Cash Flow: -76M Q3 '23 — Net Income: -65.7M Q4 '23 — Revenue: -1K Q4 '23 — Operating Cash Flow: -89.2M Q4 '23 — Free Cash Flow: -89.3M Q4 '23 — Net Income: -83.5M Q1 '24 — Revenue: 10M Q1 '24 — Operating Cash Flow: -50.3M Q1 '24 — Free Cash Flow: -52.1M Q1 '24 — Net Income: -81.4M Q2 '24 — Revenue: 0 Q2 '24 — Operating Cash Flow: -65.8M Q2 '24 — Free Cash Flow: -65.8M Q2 '24 — Net Income: -92.2M Q3 '24 — Revenue: 0 Q3 '24 — Operating Cash Flow: -75.1M Q3 '24 — Free Cash Flow: -75.3M Q3 '24 — Net Income: -88.1M Q4 '24 — Revenue: 0 Q4 '24 — Operating Cash Flow: -57.9M Q4 '24 — Free Cash Flow: -57.9M Q4 '24 — Net Income: -76M Q1 '25 — Revenue: 7.7M Q1 '25 — Operating Cash Flow: -73.2M Q1 '25 — Free Cash Flow: -73.6M Q1 '25 — Net Income: -77.1M Q2 '25 — Revenue: 677K Q2 '25 — Operating Cash Flow: -55.3M Q2 '25 — Free Cash Flow: -55.3M Q2 '25 — Net Income: -70.4M Q3 '25 — Revenue: 0 Q3 '25 — Operating Cash Flow: -62.1M Q3 '25 — Free Cash Flow: -62.1M Q3 '25 — Net Income: -74.1M Q4 '25 — Revenue: 7M Q4 '25 — Operating Cash Flow: -44.9M Q4 '25 — Free Cash Flow: -44.9M Q4 '25 — Net Income: -54.9M Q1 '26 — Revenue: 3M Q1 '26 — Operating Cash Flow: -51.1M Q1 '26 — Net Income: -73.3M Q2 '26 — Revenue: 350K Q2 '26 — Operating Cash Flow: -54.1M Q2 '26 — Net Income: -83.7M -75M -50M -25M 0 25M 50M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.7
SBC / sales 466.8%
ROIC -31.9%
Accruals -7.6%
Asset turnover 0.011×
FCF margin -2054.3%
OCF margin -2050.3%
ROA -29.6%
ROCE -33.9%
ROE -32.1%
EBITDA margin —
Gross margin —
OCF / EBIT —
OE margin —
Oper. margin —
Profit margin —

2 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.7
Current ratio 18.3×
ND/EBITDA —
Cash runway 0.57 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 18.3×
F-score 3.9 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.7
Sales CAGR 4Y +50.1%
Sales/sh Y/Y +3.1%
Sales Q/Q -48.3%
Shares change +20.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.